Mylan Pharmaceuticals Inc. v. Eurand, Inc.
568 U.S. 1123, 133 S. Ct. 933, 184 L. Ed. 2d 725, 81 U.S.L.W. 3388, 2013 WL 141183, 2013 U.S. LEXIS 846
This text of 568 U.S. 1123 (Mylan Pharmaceuticals Inc. v. Eurand, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Mylan Pharmaceuticals Inc. v. Eurand, Inc., 568 U.S. 1123, 133 S. Ct. 933, 184 L. Ed. 2d 725, 81 U.S.L.W. 3388, 2013 WL 141183, 2013 U.S. LEXIS 846 (2013).
Opinion
C. A. Fed. Cir. Certiorari denied.
Free access — add to your briefcase to read the full text and ask questions with AI
Cite This Page — Counsel Stack
Bluebook (online)
568 U.S. 1123, 133 S. Ct. 933, 184 L. Ed. 2d 725, 81 U.S.L.W. 3388, 2013 WL 141183, 2013 U.S. LEXIS 846, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mylan-pharmaceuticals-inc-v-eurand-inc-scotus-2013.